FDA Looking For Other Primary Endpoints In CHF Trials For ICDs, Pacers
This article was originally published in The Gray Sheet
Executive Summary
Peak VO2 levels will be considered a viable primary endpoint by FDA in reviewing ICDs and pacemakers for congestive heart failure